Cargando…

FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer

BACKGROUND: FK506-binding protein 12 (FKBP12) is abundant, ubiquitously expressed cytoplasmic protein with multiple functions in cell signaling transduction. Recently, we reported a novel function for FKBP12 in oncoprotein mouse double minute 2 (MDM2) self-ubiquitination and degradation, which great...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Mingyou, Wang, Jun, Yang, Qin, Wang, Yu, Li, Jiansha, Xiong, Jing, Zhou, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769097/ https://www.ncbi.nlm.nih.gov/pubmed/31428819 http://dx.doi.org/10.1007/s00280-019-03923-1

Ejemplares similares

A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
por: de la Fuente, Ana, et al.
Publicado: (2022)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2
por: Liu, T, et al.
Publicado: (2017)

FKBP51 and FKBP12.6—Novel and tight interactors of Glomulin
por: Hähle, Andreas, et al.
Publicado: (2019)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer
por: Xiong, Jing, et al.
Publicado: (2017)

FKBP12 Activates the Cardiac Ryanodine Receptor Ca(2+)-Release Channel and Is Antagonised by FKBP12.6
por: Galfré, Elena, et al.
Publicado: (2012)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
por: Mori, Hitomi, et al.
Publicado: (2016)

Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients
por: Frères, Pierre, et al.
Publicado: (2018)

ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex
por: Williams, Eleanor, et al.
Publicado: (2021)

Effect of FKBP12-Derived Intracellular Peptides on Rapamycin-Induced FKBP–FRB Interaction and Autophagy
por: Parada, Carolina A., et al.
Publicado: (2022)

Mounting evidence of FKBP12 implication in neurodegeneration
por: Caminati, Gabriella, et al.
Publicado: (2020)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

FKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer
por: Habara, Makoto, et al.
Publicado: (2022)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment
por: Cai, Fengfeng, et al.
Publicado: (2019)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)

Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
por: Dean, Matthew, et al.
Publicado: (2023)

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
por: Beaudry, Rhys I., et al.
Publicado: (2019)

Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus
por: Falloon, Katie, et al.
Publicado: (2015)

FKBP4 is a malignant indicator in luminal A subtype of breast cancer
por: Xiong, Hanchu, et al.
Publicado: (2020)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen
por: Dong, Zhaoying, et al.
Publicado: (2021)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
por: Jiang, Cui, et al.
Publicado: (2019)

Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
por: Wang, Yuehan, et al.
Publicado: (2023)

Case Report: “Area of Focus” Atypical Trichinellosis and Fascioliasis Coinfection
por: Wang, Meng, et al.
Publicado: (2022)

Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
por: Magni, Martina, et al.
Publicado: (2019)

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
por: West, Nathan R, et al.
Publicado: (2011)

Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions
por: Nasr, Arash Boroumand, et al.
Publicado: (2015)

Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer
por: Xiong, Jing, et al.
Publicado: (2016)

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
por: Dai, Kun, et al.
Publicado: (2015)

Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
por: Mulligan, Jude M., et al.
Publicado: (2014)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
por: Liu, Chang, et al.
Publicado: (2022)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
por: Fu, Changfang, et al.
Publicado: (2021)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n8r0it2659ek1kephqg7hm139c